Kazaks Alexandra G, Uriu-Adams Janet Y, Albertson Timothy E, Shenoy Sonia F, Stern Judith S
Department of Nutrition and Exercise Science, Bastyr University, Kenmore, Washington 98028-4966, USA.
J Asthma. 2010 Feb;47(1):83-92. doi: 10.3109/02770900903331127.
Epidemiological data shows low dietary magnesium(Mg) may be related to incidence and progression of asthma.
To determine if long term(6.5 month) treatment with oral Mg would improve asthma control and increase serum measures of Mg status in men and women with mild-to-moderate asthma.
55 males and females aged 21 to 55 years with mild to moderate asthma according to the 2002 National Heart, Lung, and Blood Institute(NHLBI) and Asthma Education and Prevention Program(NAEPP) guidelines and who used only beta-agonists or inhaled corticosteroids(ICS) as asthma medications were enrolled.
Subjects were randomly assigned to consume 340 mg(170 mg twice a day) of Mg or a placebo for 6.5 months.
Multiple measures of Mg status including serum, erythrocyte, urine, dietary, ionized and IV Mg were measured.
markers of asthma control were: methacholine challenge test(MCCT) and pulmonary function test(PFT) results. Subjective validated questionnaires on asthma quality of life(AQLQ) and control(ACQ) were completed by participants. Markers of inflammation, including c-reactive protein(CRP) and exhaled nitric oxide(eNO) were determined.
The concentration of methacholine required to cause a 20% drop in forced expiratory volume in in minute(FEV(1)) increased significantly from baseline to month 6 within the Mg group. Peak expiratory flow rate(PEFR) showed a 5.8% predicted improvement over time(P = 0.03) in those consuming the Mg. There was significant improvement in AQLQ mean score units(P < 0.01) and in overall ACQ score only in the Mg group(P = 0.05) after 6.5 months of supplementation. Despite these improvements, there were no significant changes in any of the markers of Mg status.
Adults who received oral Mg supplements showed improvement in objective measures of bronchial reactivity to methacholine and PEFR and in subjective measures of asthma control and quality of life.
流行病学数据显示，饮食中镁（Mg）含量低可能与哮喘的发生和发展有关。
确定口服镁进行长期（6.5个月）治疗是否会改善轻至中度哮喘男性和女性的哮喘控制情况，并提高血清镁水平的检测指标。
根据2002年美国国立心肺血液研究所（NHLBI）和哮喘教育与预防计划（NAEPP）指南，选取55名年龄在21至55岁之间、患有轻至中度哮喘且仅使用β受体激动剂或吸入性糖皮质激素（ICS）作为哮喘药物的男性和女性。
将研究对象随机分为两组，一组每天服用340毫克（170毫克，每日两次）镁，另一组服用安慰剂，为期6.5个月。
测量多种镁水平指标，包括血清、红细胞、尿液、饮食、离子化和静脉注射镁。
哮喘控制的指标为：乙酰甲胆碱激发试验（MCCT）和肺功能测试（PFT）结果。参与者完成了关于哮喘生活质量（AQLQ）和控制情况（ACQ）的主观有效问卷。测定炎症标志物，包括C反应蛋白（CRP）和呼出一氧化氮（eNO）。
在镁组中，使第一秒用力呼气容积（FEV₁）下降20%所需的乙酰甲胆碱浓度从基线到第6个月显著增加。服用镁的人群中，呼气峰值流速（PEFR）随时间推移显示出比预测值高5.8%的改善（P = 0.03）。补充镁6.5个月后，仅镁组的AQLQ平均得分单位有显著改善（P < 0.01），总体ACQ得分也有显著改善（P = 0.05）。尽管有这些改善，但镁水平的任何指标均无显著变化。
接受口服镁补充剂的成年人在乙酰甲胆碱支气管反应性和PEFR的客观指标以及哮喘控制和生活质量的主观指标方面均有改善。
